Ann Gidner, CEO
Appointed: May 9, 2022.
Qualifications: MSc Chemical Engineering Bioprocessing, Lund University and École Nationale Supérieure d’Ingénieurs de Génie Chimique de Toulouse. MBA, Lund University. Diplôme de Francais, Étoile, Paris.
Experience: Ann has 25+ years of experience from Life Science management internationally, with a significant track record in strategic development, focused leadship, deal making and sales growth. Generating steep growth in leading, international Pharma CDMO corporations took her to senior global positions in the US and Germany. She has also been leading internationalization of mid-sized Life Science companies in Sweden and Germany, as well as building up Pharma technology licencing internationally. Recent years have given experience from CEO and Board positions in listed Swedish Life Science start-ups.
Previous roles: Previous to Ziccum, Ann was the CEO of SelectImmune Pharma AB, AcuCort AB and Monocl AB, as well as Head of the Inceptua CTS Business unit in Berlin, Germany and Licensing Director at Novozymes Biopharma in Copenhagen, Denmark. Furthermore, she held senior Global Business Development and Sales & Marketing Director roles in Cambrex Corp based in New Jersey, USA and Lanxess GmbH in Leverkusen, Germany. She has also been in Pharmaceutical manufacturing and Engineering management roles. Currently Ann holds a board position in Iconovo AB, after SenzaGen AB.
Ownership: 75 000 shares and 100 000 warrants.
Frida Hjelmberg, CFO
Appointed: January 1, 2021.
Qualifications: MBA (Master Business Administration), Lund University and Hong Kong University of Science and Technology.
Experience: Frida is an experienced CFO with a strong background in controlling, accounting and auditing. She has extensive leadership and management experience, successfully leading major projects in outsourcing, acquisitions, mergers, restructuring and systems implementations.
Previous roles: Prior to Ziccum, Frida was CFO for Spares Nordic, a growth company in e-commerce. Previously, Frida has occupied a wide range of management and executive positions, including Head of Accounting at Egmont, Business Controller and Financial Analyst at RSA Insurance Group (Codan/Trygg-Hansa) and Auditor at KPMG.
Ownership: 1 900 shares and 39 364 warrants.
Fabrice Rose, Scientific Director
Appointed: Joined Ziccum August 2019, appointed Senior Formulation Specialist July 2020, appointed Scientific Director August 2022.
Qualifications: BSc in Pharmaceutical Development and Production at the Conservatoire National des Arts et Métiers Conservatoire, Paris. DEUST in Production and Quality in Pharmaceutical Industries, Formulation and Control quality, Aix-Marseille University, Marseille.
Experience: Fabrice is the author or co-author of 16 peer-reviewed publications on vaccine formulation. His 20 years’ plus experience in formulation and drug delivery includes ten year’s lab work specializing in the design and characterization of nanoparticulate vaccine formulations and investigating the physical stability of protein antigens. Highly result-oriented, Fabrice’s extensive industry experience has been characterized by his determination, resourcefulness and commitment to solving new challenges with a creative and strategic mindset.
Previous roles: Fabrice has extensive industrial and academic experience in formulation. He was a Laboratory specialist at the University of Copenhagen’s Faculty of Health and Medical Sciences, designing and characterizing vaccine formulations. He was a scientist at SOLVE contract analytical lab (running specialized analytical instrumentation), he worked at Catalent (the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products) in formulation, preformulation and stability studies for oral dosage forms, as well as other roles throughout Europe.
Ownership: 1000 warrants.
Louise Egeblad, External Projects Manager
Appointed: Recruited April 2019, appointed External Projects Manager August 2022
Qualifications: PhD in Biochemistry at Swedish University of Agricultural Sciences, SLU. MSc in Chemistry and Molecular Biology at Roskilde University, Denmark.
Experience: Louise has extensive experience as a Project Manager in industrial biotech organizations. As project manager for drug development projects, she has a broad knowledge about the different steps from Research & Development to Clinical trials. She has authored or co-authored four publications and is a flexible team player who is strongly goal oriented.
Previous roles: Louise has been Project Manager at Ziccum and Spago Nanomedical AB (a Swedish biotech developing nanomaterials for cancer diagnostics and treatment).
Ownership: 1005 shares